NuPathe plans Zelrix migraine patch refiling in US for first half of 2012
This article was originally published in Scrip
Executive Summary
Share of NuPathe climbed as high as 7.3%, or 20 cents, on 15 November after the company revealed that it plans to resubmit its new drug application (NDA) for its transdermal sumatriptan migraine patch Zelrix (NP101) to the US FDA in the first half of 2012.